MX375934B - Composiciones farmaceuticas que comprenden agentes antibacterianos. - Google Patents

Composiciones farmaceuticas que comprenden agentes antibacterianos.

Info

Publication number
MX375934B
MX375934B MX2016005161A MX2016005161A MX375934B MX 375934 B MX375934 B MX 375934B MX 2016005161 A MX2016005161 A MX 2016005161A MX 2016005161 A MX2016005161 A MX 2016005161A MX 375934 B MX375934 B MX 375934B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
antibacterial agents
compositions including
including antibacterial
pharmaceutically acceptable
Prior art date
Application number
MX2016005161A
Other languages
English (en)
Spanish (es)
Other versions
MX2016005161A (es
Inventor
Mahesh Vithalbhai Patel
Sachin Bhagwat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2016005161A publication Critical patent/MX2016005161A/es
Publication of MX375934B publication Critical patent/MX375934B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
MX2016005161A 2013-10-22 2014-10-22 Composiciones farmaceuticas que comprenden agentes antibacterianos. MX375934B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3309MU2013 IN2013MU03309A (enExample) 2013-10-22 2014-10-22

Publications (2)

Publication Number Publication Date
MX2016005161A MX2016005161A (es) 2016-10-05
MX375934B true MX375934B (es) 2025-03-07

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005161A MX375934B (es) 2013-10-22 2014-10-22 Composiciones farmaceuticas que comprenden agentes antibacterianos.

Country Status (18)

Country Link
US (1) US9827235B2 (enExample)
EP (1) EP3060213B1 (enExample)
JP (2) JP2016538258A (enExample)
KR (1) KR102340010B1 (enExample)
CN (2) CN106102741A (enExample)
AU (1) AU2014338612C1 (enExample)
BR (1) BR112016008979B1 (enExample)
CA (1) CA2928364C (enExample)
DK (1) DK3060213T3 (enExample)
ES (1) ES2902456T3 (enExample)
HU (1) HUE057504T2 (enExample)
IN (1) IN2013MU03309A (enExample)
MX (1) MX375934B (enExample)
NZ (1) NZ719215A (enExample)
PL (1) PL3060213T3 (enExample)
PT (1) PT3060213T (enExample)
RU (1) RU2702361C2 (enExample)
WO (1) WO2015059643A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
MX2007007235A (es) * 2004-12-17 2007-10-19 Venus Remedies Ltd Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
RU2366450C1 (ru) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
CA2842777C (en) * 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
HUE046893T2 (hu) * 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
AU2014206087A1 (en) * 2013-01-14 2015-05-28 Wockhardt Limited Compositions and methods for treating bacterial infections

Also Published As

Publication number Publication date
CN113577084A (zh) 2021-11-02
IN2013MU03309A (enExample) 2015-07-17
AU2014338612B2 (en) 2019-12-19
PL3060213T3 (pl) 2022-02-14
US20160303104A1 (en) 2016-10-20
KR20160072254A (ko) 2016-06-22
DK3060213T3 (da) 2022-01-03
WO2015059643A1 (en) 2015-04-30
RU2016115376A (ru) 2017-11-28
NZ719215A (en) 2020-04-24
KR102340010B1 (ko) 2021-12-16
PT3060213T (pt) 2021-12-24
CA2928364A1 (en) 2015-04-30
ES2902456T3 (es) 2022-03-28
RU2702361C2 (ru) 2019-10-08
CA2928364C (en) 2021-11-23
CN106102741A (zh) 2016-11-09
AU2014338612C1 (en) 2020-09-24
RU2016115376A3 (enExample) 2018-07-02
US9827235B2 (en) 2017-11-28
JP2019116508A (ja) 2019-07-18
HUE057504T2 (hu) 2022-05-28
BR112016008979A2 (enExample) 2017-08-01
MX2016005161A (es) 2016-10-05
EP3060213A1 (en) 2016-08-31
JP2016538258A (ja) 2016-12-08
BR112016008979B1 (pt) 2023-04-25
EP3060213B1 (en) 2021-10-13
JP6886996B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
CU20160006A7 (es) Derivados de piperidinil-indol como inhibidores de factor de complemento b
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
MX382601B (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
BR112018074985A2 (pt) composições antibacterianas
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
MX383032B (es) Formulaciones farmaceuticas inyectables de lefamulina.
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2016005160A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016005161A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2014MU00859A (enExample)
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
IN2013MU03421A (enExample)
MX2017010992A (es) Composiciones farmaceuticas estables que comprenden agente antibacteriano.

Legal Events

Date Code Title Description
FG Grant or registration